XML 37 R30.htm IDEA: XBRL DOCUMENT

Segment information (Tables)

9 Months Ended

Sep. 30, 2025

Schedule of segment financial information

The table below is a summary of the segment net loss, including significant segment expense categories (in thousands):


	Three Months Ended September 30,						Nine Months Ended September 30,
	2025			2024			2025			2024
Collaboration revenue	$	—		$	2,910		$	6,941		$	6,303
Less:
In-process research and development		—			(6,706	)		—			(124,972	)
Direct research and development expenses(1)
Varegacestat		(12,495	)		(9,621	)		(39,615	)		(14,397	)
IM-1021		(2,874	)		(4,456	)		(7,669	)		(14,865	)
IM-3050		(2,104	)		(4,080	)		(4,149	)		(9,234	)
Other product candidates		(17,623	)		(10,917	)		(35,672	)		(25,418	)
Indirect research and development(2)		(14,097	)		(8,126	)		(39,411	)		(17,738	)
General and administrative(3)		(10,945	)		(9,526	)		(31,677	)		(22,509	)
Total operating expenses		(60,138	)		(53,432	)		(158,193	)		(229,133	)
Loss from operations		(60,138	)		(50,522	)		(151,252	)		(222,830	)
Interest income		2,681			3,422			8,758			10,116
Net loss	$	(57,457	)	$	(47,100	)	$	(142,494	)	$	(212,714	)

(1)

Direct research and development expenses include external costs, such as costs related to laboratory materials and services, manufacturing, outsourced research, product development, and clinical trial costs, including fees paid to investigators, consultants, central laboratories and CROs to specific product candidates.

(2)

Indirect research and development expenses include personnel salary, benefit and share-based compensation costs, depreciation and amortization and certain overhead expenses.

(3)

General and administrative expenses include personnel salary, benefit and share-based compensation costs, legal fees, professional fees for accounting, auditing, tax and consulting services, insurance costs, travel, depreciation and amortization, and certain overhead expenses.